Form 4: HilleVax Director Jeryl L Hilleman Acquires 22,500 Stock Options

Director Jeryl L Hilleman acquired 22,500 stock options in HilleVax, Inc. on June 6, 2024, according to a Form 4 filing with the SEC.

Summary

• On June 6, 2024, Jeryl L Hilleman, a director of HilleVax, Inc. (HLVX), was granted 22,500 stock options at an exercise price of $13.75.
• The options were granted as part of the company's non-employee director compensation program.
• The options will vest on the earlier of the first anniversary of the grant date (June 6, 2025) or the next annual meeting of stockholders, contingent upon continued service on the board.
• Following the transaction, Hilleman directly owns 22,500 derivative securities.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to director compensation, which is generally viewed neutrally to positively as it aligns interests. There are no indications of negative sentiment.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service on the board.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

Stock option grants are a common form of compensation for directors, aligning their interests with the long-term performance of the company. This is a standard practice in the biotech industry to attract and retain qualified board members.

Comparison to Industry Standards

• Director compensation packages, including stock options, vary widely across the biotech industry depending on company size, stage of development, and board responsibilities.
• Comparing HilleVax's director compensation to companies like Moderna, BioNTech, or Novavax would provide a broader context, but specific details of those packages are not available in this document.
• Generally, stock option grants are structured to incentivize long-term value creation and align director interests with shareholder returns, which is consistent with industry norms.

Stakeholder Impact

• The stock option grant has a minor positive impact on shareholders by aligning director interests with long-term company performance.

Key Dates

Keywords

Form 4, HilleVax, Stock Options, Director Compensation, Jeryl L Hilleman, HLVX